As paclitaxel does not directly act on the PI3K/AKT signaling pathway, we speculated that PSD may act synergistically to enhance the sensitivity of lung adenocarcinoma cells to paclitaxel. The gene discussed is AKT1; the disease is lung adenocarcinoma.